Feedback
Settings

Settings

Goto Application

4,147 results
Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 415
1.WO/2021/009692TRIPARTITE SYSTEMS FOR PROTEIN DIMERIZATION AND METHODS OF USE
WO - 21.01.2021
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
 Appl.No PCT/IB2020/056657 Applicant MEDIMMUNE LIMITED Inventor BAMBER, Lisa
The disclosure provides compositions and methods that make use of a target protein that is capable of binding to a small molecule in order to form a complex, and a binding member that specifically binds to the complex, wherein the target protein is derived from a non-human protein and the small molecule is an inhibitor of the non-human protein. The non-human protein may be derived from a viral, bacterial, fungal or protozoal protein. These compositions and methods permit the controlled interaction of polypeptides that are individually fused to the target protein and binding member, respectively, and can be used to control the activity of dimerization-inducible proteins such as split transcription factors and split chimeric antigen receptors through the addition of the small molecule. The disclosure provides expression vectors, binding members, dimerization-inducible proteins, nucleic acids, cells, viral particles, kits, systems and methods that involve these components.
2.WO/2021/011826PROCESS OF MAKING MEMBRANE LIPID COATED NANOPARTICLES
WO - 21.01.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
 Appl.No PCT/US2020/042420 Applicant COASTAR THERAPEUTICS INC. Inventor CHUNG, Eddie, Yocon
Disclosed is a process of making a nanoparticle comprising an inner core comprising a virus and an outer surface comprising a cellular membrane derived from a cell via extrusion.
3.WO/2021/003867MONOCLONAL ANTIBODY 10G12 AND APPLICATION THEREOF
WO - 14.01.2021
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No PCT/CN2019/110042 Applicant ACADEMY OF MILITARY MEDICAL SCIENCE Inventor YANG, Zhixin
Disclosed are a monoclonal antibody 10G12 and an application thereof. The present invention provides a monoclonal antibody, comprising a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises three complementarity-determining regions, i.e., HCDR1, HCDR2, and HCDR3. The light chain variable region comprises three complementarity-determining regions, i.e., LCDR1, LCDR2, and LCDR3. The HCDR1, HCDR2, and HCDR3 are sequentially shown in sequence 2 of the sequence table from the N-terminus at positions 26-33, positions 51-66, and positions 97-109. The LCDR1, LCDR2, and LCDR3 are sequentially shown in sequence 4 of the sequence table from the N-terminus at positions 27-37, positions 55-57, and positions 94-102. On the basis of the clinical requirement, the inventors of the present invention have discovered an antibody 10G12 against human adenovirus type 7, which can be used to prevent adenovirus infection, and therefore has important biological and medical significance.
4.20210000945VECTOR CO-EXPRESSING VACCINE AND COSTIMULATORY MOLECULES
US - 07.01.2021
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
 Appl.No 16937766 Applicant Heat Biologics, Inc. Inventor Taylor SCHREIBER

Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.

5.20210002354METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA
US - 07.01.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 16977327 Applicant The University of Chicago Inventor Patrick Wilson

Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

6.20200407428THERAPEUTIC ANTIBODIES TO MARBURG VIRUS
US - 31.12.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 16491672 Applicant The Government of the United States of America as Represented by the Secretary of the Army Inventor Philippe THULLIER

Provided here are immunoglobulins and compositions containing one or more of said immunoglobulins reactive to a strain of Marburg virus. The immunoglobulins and compositions comprising said immunoglobulins can be used prophylactically to prevent a Marburg virus infection or to treat a patient that has been exposed to a Marburg virus in order to reduce a symptom.

7.20200397899METHOD OF TREATING INFLUENZA A
US - 24.12.2020
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
 Appl.No 16984827 Applicant MEDIMMUNE, LLC Inventor Nicole Kallewaard-Lelay

Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.

8.3753949ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF
EP - 23.12.2020
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No 20177206 Applicant HUMABS BIOMED SA Inventor CORTI DAVIDE
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and potently neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The invention also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.
9.WO/2020/251834ANTIBODIES AND METHODS FOR TREATMENT OF VIRAL INFECTIONS
WO - 17.12.2020
Int.Class A61K 31/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
 Appl.No PCT/US2020/036183 Applicant THE ROCKEFELLER UNIVERSITY Inventor RAVETCH, Jeffrey, V.
The present invention provides antibodies that are capable of activating dendritic cell maturation and/or inducing a protective CDS response. The disclosed antibodies can be used to treat or inhibit viral infections, including prophylaxis and treatment of influenza A infection. The invention also provides nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies.
10.20200390888NOVEL AAV MEDIATED INFLUENZA VACCINES
US - 17.12.2020
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
 Appl.No 16935121 Applicant The Trustees of the University of Pennsylvania Inventor Maria P. Limberis

A non-replicating recombinant adeno-associated associated virus (rAAV) having an AAV capsid having packaged therein a vector genome which comprises AAV inverted terminal repeat sequences and at least one nucleic acid sequence encoding four different immunoglobulin regions (a), (b), (c) and (d) is provided. The rAAV-expressed immunoglobulins are useful for providing passive immunization against influenza A and influenza B. Also described herein are compositions containing the rAAV. Methods of vaccinating patients against influenza are provided.

# -